Ipamorelin triggers GH hypersecretion but cannot rescue IGF-1 axis in STZ diabetic mice
Background
Type 1 diabetes is characterised by profound disruption of the GH/IGF-1 axis: elevated GH secretion coexists paradoxically with low circulating IGF-1 due to hepatic GH receptor resistance. This uncoupling is clinically important because IGF-1 deficiency contributes to poor growth, impaired tissue repair, and metabolic dysfunction. Streptozotocin (STZ) rat models have been the workhorse for studying this axis, but their fidelity to human type 1 diabetes has been questioned. Understanding whether a GH secretagogue can bypass hepatic resistance — or whether it merely amplifies already-pathological GH hypersecretion — is critical for evaluating ipamorelin and related compounds in a diabetic context.
Study Design
Female mice received IV streptozotocin to induce diabetes; nondiabetic females served as controls. On day 14, animals received a single IV injection of ipamorelin (GH secretagogue) or saline. Blood was collected at baseline and 10 minutes post-injection. Livers were harvested for qPCR measurement of GH receptor, GH-binding protein, and IGF-1 mRNA, plus hepatic IGF-1 peptide quantification. Serum GH and IGF-1 were measured by immunoassay (ELISA-class). Primary endpoints were peak serum GH, serum IGF-1, and hepatic IGF-1 mRNA/peptide responses to stimulation.
Results
Following ipamorelin injection, serum GH reached 150 ± 35 µg/L in diabetic mice versus 62 ± 11 µg/L in nondiabetic mice (p < .05), confirming pronounced GH hypersecretion in the diabetic state. Serum IGF-1 was lower in diabetic than nondiabetic animals at baseline, and rose after stimulation only in nondiabetic animals; diabetic mice showed no detectable IGF-1 increase.
Hepatic
GH receptormRNA,GH-binding proteinmRNA,IGF-1mRNA, and IGF-1 peptide all increased in nondiabetic mice after ipamorelin-driven GH stimulation — yet all of these parameters remained at their already-low levels in diabetic animals, completely unaffected by the secretagogue challenge.
The dissociation between a ~2.4-fold higher peak GH in diabetic mice and zero hepatic IGF-1 response demonstrates near-complete hepatic GH receptor resistance in the STZ mouse model. Critically, the STZ mouse recapitulated the clinical signature of human type 1 diabetes — GH hypersecretion plus peripheral GH resistance — more faithfully than STZ rat models have been reported to do.
Key Findings
- Ipamorelin-stimulated GH: 150 ± 35 µg/L (diabetic) vs 62 ± 11 µg/L (nondiabetic), p < .05
- Serum IGF-1 rose post-ipamorelin in nondiabetic mice only; no response in diabetic mice
- Hepatic GH receptor, GH-binding protein, and IGF-1 mRNA unaffected by ipamorelin in diabetic mice
- STZ mice replicate human type 1 diabetes GH/IGF-1 axis disruption better than STZ rats
- Complete hepatic GH resistance persisted despite supraphysiological GH secretion in diabetic animals
Why It Matters
Practitioners using ipamorelin or GHRP-6 to elevate IGF-1 should note that active or poorly-controlled type 1 diabetes may render these secretagogues incapable of raising IGF-1, because the hepatic GH receptor pathway is functionally silenced regardless of how much GH is released. The anabolic benefit of GH secretagogues depends entirely on an intact GH receptor–IGF-1 signalling cascade in the liver; in the insulin-deficient state that cascade is broken at the receptor level. Clinically, this implies that co-administration of insulin to restore hepatic GH sensitivity would be a prerequisite before secretagogue protocols yield meaningful IGF-1 elevation. The STZ mouse is validated here as a superior preclinical model for further testing of GH-axis interventions in diabetes, meaning future drug-development findings in this model should translate more reliably to humans than prior STZ-rat data.
